Comparison of transesophageal echocardiographic analysis and circulating biomarker expression profile in calcific aortic valve disease

Journal of Heart Valve Disease

Volumn 22, Issue 2, 2013, Pages 156-165

  Sainger, Rachana ^a   Grau, Juan B ^b   Branchetti, Emanuela ^a   Poggio, Paolo ^a,c   Lai, Eric ^a   Koka, Erblina ^a   Vernick, William J ^a   Gorman, Robert C ^a   Bavaria, Joseph E ^a   Ferrari, Giovanni ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b College of Physicians and Surgeons ^*  (United States)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; FETUIN A; OSTEOPONTIN; PARATHYROID HORMONE; AHSG PROTEIN, HUMAN; ARGININE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DRUG DERIVATIVE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; AORTA ATHEROSCLEROSIS; AORTA STENOSIS; AORTA VALVE DISEASE; ARTICLE; BIOMINERALIZATION; CALCIFICATION; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CARDIAC PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HALF LIFE TIME; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; AORTA VALVE; AORTA VALVE STENOSIS; BLOOD; CALCINOSIS; CASE CONTROL STUDY; ECHOGRAPHY; METABOLISM; PATHOLOGY; SCLEROSIS; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-2-HS-GLYCOPROTEIN; AORTIC VALVE; AORTIC VALVE STENOSIS; ARGININE; BIOLOGICAL MARKERS; CALCINOSIS; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; OSTEOPONTIN; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; SCLEROSIS; SEVERITY OF ILLNESS INDEX;

MLCS; MLOWN;

EID: 84880578364     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Beckmann E, Grau JB, Sainger R, Poggio P, Ferrari G. Insights into the use of biomarkers in calcific aortic valve disease. J Heart Valve Dis 2010;19:441-452
2. Helske S, Kupari M, Lindstedt KA, Kovanen PT. Aortic valve stenosis: An active atheroinflammatory process. Curr Opin Lipidol 2007;18:483-491
3. Otto CM. Calcific aortic valve disease: New concepts. Semin Thorac Cardiovasc Surg 2010;22:276-284
4. Parolari A, Loardi C, Mussoni L, et al. Nonrheumatic calcific aortic stenosis: An overview from basic science to pharmacological prevention. Eur J Cardiothorac Surg 2009;35:493-504
5. Gharacholou SM, Karon BL, Shub C, Pellikka PA. Aortic valve sclerosis and clinical outcomes: Moving toward a definition. Am J Med 2011;124:103-110
6. Helske S, Otto CM. Lipid lowering in aortic stenosis: Still some light at the end of the tunnel? Circulation 2009;119:2653-2655
7. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999;341:142-147
8. Prasad Y, Bhalodkar NC. Aortic sclerosis - a marker of coronary atherosclerosis. Clin Cardiol 2004;27:671-673
9. Novaro GM, Aronow HD, Mayer-Sabik E, Griffin BP. Plasma homocysteine and calcific aortic valve disease. Heart 2004;90:802-803
10. O'Brien KD. Pathogenesis of calcific aortic valve disease: A disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 2006;26:1721-1728
11. Akat K, Kaden JJ, Schmitz F, et al. Calcium metabolism in adults with severe aortic valve stenosis and preserved renal function. Am J Cardiol 2010;105:862-864
12. Linhartova K, Veselka J, Sterbakova G, Racek J, Topolcan O, Cerbak R. Parathyroid hormone and vitamin D levels are independently associated with calcific aortic stenosis. Circ J 2008;72:245-250
13. Cho HJ, Kim HS. Osteopontin: A multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep 2009;11:206-213
14. Grau JB, Poggio P, Sainger R, et al. Analysis of osteopontin levels for the identification of asymptomatic patients with calcific aortic valve disease. Ann Thorac Surg 2012;93:79-86
15. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: Data from the Heart and Soul Study. Circulation 2007;115:2533-2539
16. Bergler-Klein J. Natriuretic peptides in the management of aortic stenosis. Curr Cardiol Rep 2009;11:85-93
17. Ferrari G, Sainger R, Beckmann E, et al. Validation of plasma biomarkers in degenerative calcific aortic stenosis. J Surg Res 2010;163:12-17
18. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009;22:1-23; quiz 101-102
19. Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611-617
20. Steadman CD, Ray S, Ng LL, McCann GP. Natriuretic peptides in common valvular heart disease. J Am Coll Cardiol 2010;55:2034-2048
21. Poggio P, Grau JB, Field BC, et al. Osteopontin controls endothelial cell migration in vitro and in excised human valvular tissue from patients with calcific aortic stenosis and controls. J Cell Physiol 2011;226:2139-2149
22. Sainger R, Grau JB, Poggio P, et al. Dephosphorylation of circulating human osteopontin correlates with severe valvular calcification in patients with calcific aortic valve disease. Biomarkers 2012;17:111-118
23. Kaden JJ, Reinohl JO, Blesch B, et al. Systemic and local levels of fetuin-A in calcific aortic valve stenosis. Int J Mol Med 2007;20:193-197
24. Price PA, Lim JE. The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem 2003;278:22144-22152
25. Koos R, Brandenburg V, Mahnken AH, et al. Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients. Eur Heart J 2009;30:2054-2061
26. Orlowska-Baranowska E, Baranowski R, Greszata L, Stepinska J. Brain natriuretic peptide as a marker of left ventricular hypertrophy in patients with aortic stenosis. J Heart Valve Dis 2008;17:598-605
27. Marechaux S, Hattabi M, Juthier F, et al. Clinical and echocardiographic correlates of plasma B-type natriuretic peptide levels in patients with aortic valve stenosis and normal left ventricular ejection fraction. Echocardiography 2011;28:695-702
28. Rajamannan NM, Evans FJ, Aikawa E, et al. Calcific aortic valve disease: Not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease - 2011 update. Circulation 2011;124:1783-1791
29. Aikawa E, Otto CM. Look more closely at the valve: Imaging calcific aortic valve disease. Circulation 2012;125:76-86
30. Srisawasdi P, Vanavanan S, Charoenpanichkit C, Kroll MH. The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. Am J Clin Pathol 2010;133:14-23
31. Dimitrow PP, Jawien M. Anti-inflammatory effect of atorvastatin in patients with aortic sclerosis or mild aortic stenosis independent of hypercholesterolemia. Pharmacol Rep 2010;62:1250-1254
32. Dimitrow PP, Jawien M, Gackowski A. The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. J Heart Valve Dis 2011;20:18-22
33. Parolari A, Tremoli E, Cavallotti L, et al. Do statins improve outcomes and delay the progression of non-rheumatic calcific aortic stenosis? Heart 2011;97:523-529
34. O'Brien KD, Probstfield JL, Caulfield MT, et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 2005;165:858-862